Homa Yeganegi, Senior Vice President, Global PEGPH20 Program Lead

Ms. Yeganegi brings to Halozyme extensive experience in building and leading oncology-focused Global Medical Affairs teams and has a demonstrated track record of success driving strategic data generation, opinion leader development and engagement, scientific strategy and community, including global medical information and scientific education. Ms. Yeganegi joined Halozyme in March 2016 as the Vice President of Global Medical and Scientific Affairs. As the Global Program Lead for PEGPH20 (pegvorhyaluronidase alfa), she is responsible for the commercialization strategy and operational planning for Halozyme’s investigational new drug.


Prior to Halozyme, Ms. Yeganegi served as the Vice President of Global Medical Affairs at Clovis Oncology Pharmaceuticals where she successfully supported the pre-launch activities for Rociletinib in non-small lung cancer in the U.S. and EU. She has also built and led oncology-focused Global Medical Affairs teams at Exelixis Pharmaceuticals and Onyx Pharmaceuticals.


Ms. Yeganegi received her B.S. in Biology from the University of Tehran, Iran, her M.S. in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok